Yahoo
Frankfurt - Delayed Quote EUR

TempraMed Technologies Ltd. (9DY.F)

0.1845 -0.0125 (-6.35%)
As of 8:02:39 AM GMT+1. Market Open.
Chart Range Bar
Loading chart for 9DY.F
  • Previous Close 0.1970
  • Open 0.1845
  • Bid 0.1845 x --
  • Ask 0.2440 x --
  • Day's Range 0.1845 - 0.1845
  • 52 Week Range 0.1410 - 0.8980
  • Volume 1,500
  • Avg. Volume 3,422
  • Market Cap (intraday) 14.832M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2800
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

TempraMed Technologies Ltd., a medical device technology company, develops patent-protected technology designed to serve a broad range of medical and consumer products. Its primary focus is storage and management of injectable for temperature-sensitive medications. The company provides VIVI Cap, an insulin insulation and travel case; VIVI Cap Smart, a connected insulin storage and protection; VIVI Med, a temperature medication; and VIVI Epi, a Storage and Protection for EpiPen. The company was incorporated in 2023 and is based in Burnaby, Canada.

tempramed.com

--

Full Time Employees

--

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

9DY.F
72.05%
S&P/TSX Composite index (^GSPTSE)
12.35%

1-Year Return

9DY.F
61.17%
S&P/TSX Composite index (^GSPTSE)
18.31%

3-Year Return

9DY.F
61.17%
S&P/TSX Composite index (^GSPTSE)
80.59%

5-Year Return

9DY.F
61.17%
S&P/TSX Composite index (^GSPTSE)
68.36%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.2800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More
Mobilize your Website
View Site in Mobile | Classic
Share by: